Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double‐Blind, Active Comparator– and Placebo‐Controlled Study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double‐Blind, Active Comparator– and Placebo‐Controlled Study

Published:2017-05-03 Issue:6 Volume:69 Page:1144-1153
ISSN:2326-5191
Container-title:Arthritis & Rheumatology
language:en
Short-container-title:Arthritis & Rheumatology

Author:

Blanco Francisco J.¹^ORCID,Möricke Rüdiger²,Dokoupilova Eva³,Codding Christine⁴,Neal Jeffrey⁵,Andersson Mats⁶,Rohrer Susanne⁶,Richards Hanno⁶

Affiliation:

1. Hospital Universitario A CoruñaA Coruña Spain

2. Institut für Präventive Medizin & Klinische ForschungMagdeburg Germany

3. Medical PlusUherske Hradiste Czech Republic

4. Health Research of OklahomaOklahoma City

5. Bluegrass Community ResearchLexington Kentucky

6. Novartis PharmaBasel Switzerland

Funder

Novartis Pharma AG, Basel, Switzerland

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/art.40070

Reference31 articles.

1. The Pathogenesis of Rheumatoid Arthritis

2. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases

3. The Burden of Disease in Rheumatoid Arthritis

4. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update

5. Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition

Cited by 146 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx® in Healthy Chinese Male Subjects;Drug Design, Development and Therapy;2024-08

2. A framework for longitudinal latent factor modelling of treatment response in clinical trials with applications to Psoriatic Arthritis and Rheumatoid Arthritis;Journal of Biomedical Informatics;2024-06

3. From bench to bedside - is there a role of IL-17 drugs in rheumatoid arthritis?;Expert Opinion on Investigational Drugs;2024-05-09

4. Difficult to treat rheumatoid arthritis: Sequential therapy with different personalized biological targets could be an option;European Journal of Internal Medicine;2024-05

5. Characterization of Th17 tissue-resident memory cells in non-inflamed intestinal tissue of Crohn's disease patients;Journal of Autoimmunity;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3